Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea

Posted on by

GUANGZHOU, China, Aug. 25, 2023 /PRNewswire/ — On August 23rd 2023, Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.